Evidence map›Paper›PMID 39175104›Full record

ArticleJournal of cellular and molecular medicine2024

Lycorine (Lycoris radiata)-a unique natural medicine on breast cancer.

Qinbing Xue, Bing Wang, Jie Feng, Chaoyu Li, Miao Yu, Yan Zhao, Zheng Qi

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Lycorine (Lycoris radiata)-a unique natural medicine on breast cancer.Journal of cellular and molecular medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qinbing XueEngineering Research Center for Medicine, Ministry of Education, Harbin University of Commerce, Harbin, China.
Bing WangSchool of Food Engineering, Harbin University of Commerce, Harbin, China.
Jie FengEngineering Research Center for Medicine, Ministry of Education, Harbin University of Commerce, Harbin, China.
Chaoyu LiEngineering Research Center for Medicine, Ministry of Education, Harbin University of Commerce, Harbin, China.
Miao YuEngineering Research Center for Medicine, Ministry of Education, Harbin University of Commerce, Harbin, China.
Yan ZhaoDepartment of Medical Imaging, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Zheng QiEngineering Research Center for Medicine, Ministry of Education, Harbin University of Commerce, Harbin, China.ORCID 0000-0001-7195-5902

Funding

Jinghu Program of Harbin University of Commerce 2023JHQNRC06National Natural Science Foundation of China 41702368the Key Research and Development Program of Heilongjiang Province 2022ZX02C07the Young Innovative Talents Training Program of Harbin University of Commerce 2023-KYYWF-1032
6 · The paper itself

Abstract

Breast cancer (BC) is one of the most common types of cancer among women worldwide. Lycorine (Lycoris radiata), a small molecule derived from the traditional Chinese herb Amaryllidaceae plants, has appeared potential effect on inhibiting the growth of cancer cells and inducing apoptosis in various types of cancer with minor side effects. To discuss the therapeutic effects and molecular mechanisms of lycorine on BC established by lycorine-treated S180 tumour-bearing mice in vivo. Furthermore, both the mitotic and microtubule assembly dynamics genes were performed by qPCR assays, and the protein expression associated with mitotic arrest was investigated by western blot. Lycorine was demonstrated to reduce sarcoma growth of S180 tumour-bearing mice and inhibit the proliferation of MCF-7 cells in concentration-dependent manner. Moreover, lycorine induced M phase cell cycle arrest via interfering with the mitotic apparatus regulated the expression of 20 genes and 15 proteins in cell cycle progression. Furthermore, this study confirmed that the potential effect of lycorine on BC might be mediated by cell cycle arrest in M phase for the first time. These results would be the consequence of exploitation of lycorine as a potential drug for BC therapy, however further preclinical and clinical studies are still needed.

Indexed as

Amaryllidaceae AlkaloidsBreast NeoplasmsCell ProliferationLycorisPhenanthridinesAnimalsAntineoplastic Agents, PhytogenicApoptosisCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsMiceMitosisXenograft Model Antitumor AssaysAmaryllidaceae AlkaloidsAntineoplastic Agents, PhytogeniclycorinePhenanthridinesbreast cancercell cycle arrestlycorinemitosisM‐phase

Identifiers

PMID39175104
PMCPMC11341274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.